Equities Analysts Offer Predictions for Rigel Pharmaceuticals, Inc.’s FY2024 Earnings (NASDAQ:RIGL) (2024)

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL – Free Report) – Stock analysts at HC Wainwright issued their FY2024 earnings estimates for shares of Rigel Pharmaceuticals in a research note issued to investors on Wednesday, March 6th. HC Wainwright analyst J. Pantginis expects that the biotechnology company will post earnings per share of ($0.11) for the year. HC Wainwright has a “Buy” rating and a $15.00 price objective on the stock. The consensus estimate for Rigel Pharmaceuticals’ current full-year earnings is ($0.06) per share. HC Wainwright also issued estimates for Rigel Pharmaceuticals’ Q4 2024 earnings at ($0.02) EPS and FY2025 earnings at ($0.02) EPS.

Several other equities research analysts have also commented on the stock. Citigroup boosted their price target on shares of Rigel Pharmaceuticals from $3.00 to $4.00 and gave the stock a “buy” rating in a report on Thursday, March 7th. StockNews.com raised shares of Rigel Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday. B. Riley reissued a “neutral” rating and set a $1.25 price target on shares of Rigel Pharmaceuticals in a research report on Wednesday, March 6th. Finally, Cantor Fitzgerald boosted their price target on shares of Rigel Pharmaceuticals from $2.00 to $3.00 and gave the company a “neutral” rating in a research report on Wednesday, March 6th. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $5.05.

Read Our Latest Report on Rigel Pharmaceuticals

Rigel Pharmaceuticals Trading Down 3.8 %

RIGL opened at $1.51 on Monday. The firm has a market capitalization of $264.82 million, a PE ratio of -10.07 and a beta of 0.96. The firm has a 50 day moving average of $1.32 and a two-hundred day moving average of $1.15. Rigel Pharmaceuticals has a 12-month low of $0.71 and a 12-month high of $1.96.

Institutional Trading of Rigel Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. Acadian Asset Management LLC increased its stake in shares of Rigel Pharmaceuticals by 1.7% during the third quarter. Acadian Asset Management LLC now owns 4,660,740 shares of the biotechnology company’s stock worth $5,033,000 after buying an additional 79,228 shares during the period. Principal Financial Group Inc. lifted its holdings in shares of Rigel Pharmaceuticals by 22.0% during the third quarter. Principal Financial Group Inc. now owns 121,938 shares of the biotechnology company’s stock worth $132,000 after purchasing an additional 21,962 shares during the period. Graham Capital Management L.P. lifted its holdings in shares of Rigel Pharmaceuticals by 622.5% during the second quarter. Graham Capital Management L.P. now owns 81,705 shares of the biotechnology company’s stock worth $105,000 after purchasing an additional 70,397 shares during the period. Natixis acquired a new stake in shares of Rigel Pharmaceuticals during the second quarter worth $74,000. Finally, Allspring Global Investments Holdings LLC lifted its holdings in shares of Rigel Pharmaceuticals by 28.9% during the third quarter. Allspring Global Investments Holdings LLC now owns 105,067 shares of the biotechnology company’s stock worth $113,000 after purchasing an additional 23,526 shares during the period. 63.45% of the stock is currently owned by hedge funds and other institutional investors.

Rigel Pharmaceuticals Company Profile

(Get Free Report)

Rigel Pharmaceuticals, Inc, a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; and Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test.

Featured Stories

• Five stocks we like better than Rigel Pharmaceuticals
• What Makes a Stock a Good Dividend Stock?
• Unbearably Good Investment: A Build-A-Bear Stock Analysis
• How Investors Can Identify and Successfully Trade Gap-Down Stocks
• Coinbase Stock Tempting but isn’t without its Risks
• Special Purpose Acquisition Company (SPAC) What You Need to Know
• This Industrial Products Stock is Goldman’s Favorite This Cycle

Receive News & Ratings for Rigel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rigel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.